German drug company Merck KGaA said Monday it has struck a deal to buy U.S. biotech firm SpringWorks Therapeutics for around $3.9 billion, expanding its portfolio of rare disease and cancer ...

German pharmaceutical company Merck announced Monday that it has reached an agreement to acquire US-based SpringWorks Therapeutics for $3.9 billion, a move aimed at strengthening its oncology ...

The company didn't provide an outlook for 2025. - Merck (MRK) shares rise after the company agreed to buy SpringWorks Therapeutics Inc. for $47 per share in cash, representing an equity value of ...

(RTTNews) - Merck KGaA, and SpringWorks Therapeutics, Inc. (SWTX) announced they have entered into a definitive agreement for Merck KGaA to acquire SpringWorks. The purchase price of $47 per share ...

Merck KGaA entered into a definitive agreement to acquire U.S. biopharmaceutical company SpringWorks Therapeutics in a deal valued at around $3.9 billion, confirming an earlier report in The Wall ...

It also fits with the strategic objective of strengthening Merck KGaA, Darmstadt, Germany’s Healthcare presence in the United States, the world’s largest pharmaceutical market. Upon closing ...

The Akeso (OTCPK:AKESF)-sponsored trial was designed to evaluate ivonescimab against Merck’s (MRK) Keytruda (pembrolizumab) in certain patients with non-small cell lung cancer (NSCLC).

Thimerosal, or sodium ethylmercurithiosalicylate, is a preservative used in low concentrations mainly in vaccines, cosmetics, ophthalmic and otolaryngolic medications, antitoxins, topical and ...

Germany’s Merck KGaA is paying $45 million upfront for rights to a potentially first-in-class drug for colorectal cancer (CRC) being developed by New York biotech Inspirna. The agreement gives ...

During an R&D update yesterday Merck said it is hoping to claim eight new cardiovascular therapy approvals between now and 2030, for diseases like atherosclerosis, heart failure, pulmonary ...